ClinicalTrials.Veeva

Menu

Efficacy of 311-nm Ti:Sapphire Laser Versus 308-nm Excimer Laser Treatment in Vitiligo

T

The Catholic University of Korea

Status

Unknown

Conditions

Vitiligo

Treatments

Device: 311-nm Ti:Sapphire laser
Device: 308-nm excimer laser

Study type

Interventional

Funder types

Other

Identifiers

NCT02925767
VC16DISI0088

Details and patient eligibility

About

A randomized controlled non-inferiority trial based on split-body was planned to compare the efficacy of 308-nm excimer laser and 311-nm Ti:Sapphire laser in patients with vitiligo.

Full description

The 308-nm excimer laser (EL) has been widely used for localized vitiligo. Recently, the 311-nm Ti:Sapphire laser (TSL) was developed to treat patients with vitiligo. To compare the efficacy of TSL vs. EL in the treatment of vitiligo.

A randomized controlled non-inferiority trial based on split-body was planned. The paired symmetric vitiliginous lesions will be randomized to either TSL or EL treatment groups. All lesions will be treated twice weekly for a total of 12-week period. The degree of repigmentation will be assessed as % from baseline by using a computer program every 4 weeks, and the non-inferiority margin was set at 10%. Overall 16 patients will be enrolled.

Enrollment

16 estimated patients

Sex

All

Ages

20+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age: older than 19
  • A patient with stable non-segmental vitiligo
  • A patient with symmetrical vitiligo lesions
  • A patient with the willingness to comply with the study protocol during the study period and capable of complying with it
  • A patient who signed the informed consent prior to the participation of the study and who understands that he/she has a right to withdrawal from participation in the study at any time without any disadvantages

Exclusion criteria

  • Age: lower than 20
  • A pregnant or lactating patient
  • A patient with active or spreading vitiligo
  • A patient who cannot understand the study or who does not sign the informed consent

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

16 participants in 2 patient groups

The 311-nm Ti:Sapphire laser treatment group
Experimental group
Description:
All lesions were treated twice weekly for a total of 12-week period.
Treatment:
Device: 311-nm Ti:Sapphire laser
The 308-nm excimer laser treatment group
Active Comparator group
Description:
All lesions were treated twice weekly for a total of 12-week period.
Treatment:
Device: 308-nm excimer laser

Trial contacts and locations

1

Loading...

Central trial contact

Jung Min Bae, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems